黄芪注射液预防冠状动脉介入后造影剂肾病的研究

目的观察中成药黄芪注射液对防治冠状动脉介入诊疗后造影剂相关肾病的有效性，为临床防治造影剂肾病提供新思路。方法按就诊先后随机将52例患者分成两组，从造影前12h至造影后12h，等渗盐水组用0．9％氯化钠注射液以1．0～1．5mlJ（kg·h）的滴速静脉滴注；黄芪组用黄芪注射液40mL加入5％GS，以1．0—1．5mlJ（kg·h）的滴速静脉滴注。结果黄芪组肌酐增加值（30．2±15．6VS63．7±22．4，P〈0．05）和增加百分比（10．8％4-5．2％vs26．9％±10．2％，P〈0．05），明显低于对照组，内生肌酐下降值（10．3±4．2）VS（15．1±3．9）、下降比率（9．8±3．9）VS（14．3±4．5）、CIN的发生率（11．5％VS 34．6％）亦明显低于对照组（P〈0．05）。结论黄芪注射液对CIN的发生具有较好的保护作用。

Study of Astragalus Injection on Prevention of Contrast Induced Nephrotoxity after Percutaneous Coronary Intervention

Objective To study the validity of astragalus injection on contrast induced nephrotoxity after percutaneous coronary intervention,and find out a new clinical method for prevention and treatment with it. Methods 52 patients were randomly divided into two groups： control group in Which 26 cases were treated with 0.9% NaC1 injection1.0-l.Sml/（kg·h）] and treatment group in which 26 cases were treated with astragalus injection40mL Astragalus injection were added into 250mL 5% glucose, 1.0-1.SmL/（kg＇h）]. Results There was a very significant difference between control group and treatment group in value-added（30.2 ± 15.6 vs 63.7 ± 22.4,P〈 0.05 ） and its rate （.10.8% ± 5.2% vs 26.9% ± 10.2%,P〈 0.05） of serum creatinine,the desending value（10.3 ± 4.2 vs 15.1± 3.9） and its rate（9.8 ± 3.9 vs 14.3 ± 4.5） of creatinine clearance, the rate of CIN（ 11.5% vs 34.6%） in treatment group were significantly lower than those in control group, and also had a significant difference between them（P 〈 0.05）. Conclusion Astragalus injection has a good protection on CIN.